Printer Friendly

PHARMOS CORPORATION ADDRESSES KEY COMPLIANCE ISSUES WITH SME TECHNOLOGY

 SARASOTA, Fla., May 3 /PRNewswire/ -- SubMicron Emulsion (SME) technology is a lipid-based formulation system designed to address compliance and safety issues in treating a number of eye diseases and has been tested by Pharmos (NASDAQ: PARS) in conjunction with a number of ocular therapies. The results of these studies are being presented at the Association for Research in Vision and Ophthalmology (ARVO) conference in Sarasota,
 The SME methodology is most appropriately applied to poorly water soluble compounds (lipophilic) and allows them to be solubilized by incorporating the drug of interest into a system of finely divided oil droplets. Pharmos technology permits precise drug loading of the very small oil particles, which appears to improve patient comfort for eye drops. In addition, the efficacy and sustained release of the drug reduce the number of doses necessary for therapeutic benefit.
 Human clinical trial studies being presented at ARVO tested the efficacy of a single dose of pilocarpine SME. This is the first publication of Pharmos' Phase 1 studies. The product is currently in Phase II clinical trials. The resuls show significant improvements. Most glaucoma suffers are burdened by chronic therapies requiring doses more than 4 times daily. Accompanying this inconvenience are eye irritation and temporary vision impairment.
 Researchers found that intraocular pressure can be reduced by one- third using Pharmos' SME technology and pilocarpine, a drug for treating glaucoma. Participants in the study received a single drop of either 2 percent pilocarpine-emulsion or the conventional emulsion. The volunteers were examined at one, two, six, 12 and 24 hour intervals for corrected visual acuity and intraocular pressure. Intraocular pressure dropped 33 percent in eyes treated with pilocarpine-SME and this effect lasted for at least 12 hours. Both intraocular pressure and pupil diameter returned to pre-treatment level after 24 hours. Eyes treated with conventional emulsion alone had no intraocular pressure reduction.
 The results suggest that Pharmos' SME formulated pilocarpine is sufficiently active to permit twice-a-day dosing of this well known cholinergic anti-glaucoma drug. A twice-a-day dosing which is comfortable in the eye is a significant patient benefit as compared to the current 4 to 6 dosage regimen of uncomfortable formulations.
 Pharmos Corporation is engaged in the development of novel pharmaceuticals based on innovative drug delivery technologies targeting diseases of the eye, principally glaucoma and ocular inflammation, and the brain, principally stroke end head trauma.
 -0- 5/3/93
 /CONTACT: Stephen R. Streber, president and COO of Pharmos Corporation, 212-838-0087; Donald C. Weinberger of Strategic Growth International, 212-826-9622; or Anthony J. Russo, Ph.D., of Noonan/Russo Communications, 212-979-9180, both for Pharmos Corporation/
 (PARS)


CO: Pharmos Corporation ST: New York IN: MTC SU:

AH-LR -- NY074 -- 3876 05/03/93 14:32 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 3, 1993
Words:447
Previous Article:UNIQUE APPROACH HELPS COMPANIES; FIRM COACHES TOP EXECUTIVES IN THE ART OF CHANGE
Next Article:ASTRONAUT CAPTAIN EUGENE CERNAN JOINS SPACENET USA BOARD: THE LAST ASTRONAUT TO LEAVE HIS FOOTPRINT ON THE MOON JOINS SPACENET USA BOARD
Topics:


Related Articles
PHARMOS AND PHARMATEC APPOINT NEW PRESIDENT & COO, CFO
PHARMOS COMPLETES $65 MILLION MERGER OF PHARMATEC; TO FOCUS EXPANDED TECHNOLOGY BASE ON DEVELOPMENT/COMMERCIALIZATION OF DRUGS FOR EYES,BRAIN
PHARMOS CORPORATION CONTINUING PROGRESS IN OPHTHALMIC RESEARCH
PHARMOS CORPORATION PRESENTS FIRST STUDIES ON NOVEL ANTIGLAUCOMA NEUROPROTECTIVE AGENT
PHARMOS' TREATMENT SHOWS EFFICACY IN GIANT PAPILLARY CONJUNCTIVITIS; PHARMOS REPORTS DATA FROM CLINICAL STUDIES
PHARMOS RESEARCHERS PRESENT DATA ON THE THERAPEUTIC VALUE OF HU-211, A NEUROPROTECTANT IN HEAD TRAUMA AND STROKE
PHARMOS DRUG DELIVERY SYSTEM OVERCOMES BIOLOGICAL BARRIERS
PHARMOS SUCCESSFULLY COMPLETES PHASE II TRIAL OF PILOCARPINE-SME ON 60 GLAUCOMA PATIENTS
PHARMOS CORPORATION'S NOVEL OCULAR DRUG DELIVERY SYSTEM RECEIVES ADDITIONAL PATENT
Pharmos Initiates Phase II Study to Evaluate Dexanabinol in Traumatic Head Injury Patients

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters